Loading clinical trials...
Loading clinical trials...
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
Conditions
Interventions
Donanemab
Aducanumab
Locations
31
United States
Neurology Center of North Orange County
Fullerton, California, United States
Irvine Clinical Research
Irvine, California, United States
California Neuroscience Research Medical Group, Inc.
Sherman Oaks, California, United States
Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States
JEM Research Institute
Atlantis, Florida, United States
Brain Matters Research
Delray Beach, Florida, United States
Start Date
November 16, 2021
Primary Completion Date
September 9, 2022
Completion Date
September 19, 2023
Last Updated
November 29, 2024
NCT07545473
NCT04570085
NCT07531732
NCT07290387
NCT06501495
NCT07101380
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions